Inflammatory mediators and Vascular Endothelial Growth Factor (VEGF) pathways

Inflammatory mediators and VEGF-related pathways represent a complex biological network where pro-angiogenic factors and inflammatory cytokines mutually reinforce one another to drive disease progression. Vascular Endothelial Growth Factor (VEGF) is a primary driver of angiogenesis and vascular permeability, but its expression is frequently up-regulated by inflammatory mediators such as Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-6 (IL-6) (Source: PubMed, PMID: 17641034). Conversely, VEGF can act as a pro-inflammatory agent by inducing the expression of adhesion molecules on endothelial cells, which facilitates the recruitment of leukocytes to tissues (Source: Frontiers in Immunology, 2018). This synergistic relationship is a hallmark of 'inflammatory angiogenesis,' which is critical in the pathogenesis of solid tumors, wet age-related macular degeneration, and autoimmune disorders like rheumatoid arthritis (Source: Nature Reviews Cancer, 2005). Therapeutic intervention typically involves monoclonal antibodies or small-molecule tyrosine kinase inhibitors designed to disrupt these signaling loops. While highly effective in reducing edema and tumor vascularization, targeting these pathways requires careful management of systemic side effects such as hypertension and impaired tissue repair (Source: NIH/NCI, 'Angiogenesis Inhibitors').

Other names

VEGF-inflammation axisAngiogenesis-inflammation signaling crosstalkPro-inflammatory and pro-angiogenic pathwaysVEGF-mediated inflammatory signaling

Drugs targeting these pathways function by neutralizing circulating ligands such as VEGF-A or TNF-alpha, or by competitively inhibiting their respective receptors (e.g., VEGFR2, IL-6R) to block downstream intracellular signaling cascades like MAPK/ERK and PI3K/Akt, ultimately reducing pathological blood vessel growth and inflammatory cell infiltration.